SOX1 and cholangiocarcinoma: In summary, we found that SOX1 is downregulated expression in CCA patients, it suppressed the RAF/MEK/ERK pathway by decreasing the phosphorylation of RAF, MEK, and ERK, and inhibited the proliferation of CCA cells in vitro and suppressed tumor growth in vivo.